Annals of Oncology

Elsevier BV

Journal websitePeer review: Peer review
Evaluation status available after sign-in

About the journal

Annals of Oncology is a journal published by Elsevier BV in Netherlands. It is listed in MEDLINE and PUBMED according to the sources read. Declared publication charge: 4,060 USD. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
Elsevier BV
ISSN
0923-7534 · 1569-8041
Country
Netherlands
Access
Not open access / not declared
Declared publication charge
4,060 USD
Declared peer-review model
peer_review

Index listings

  • MEDLINE · 1990-01-01
  • PUBMED · 2016-06-01
Indexing
MEDLINE · PUBMED
APC
4,060 USD
Declared review time (DOAJ)
—
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Works in OpenAlex

67139

Last recorded publication year

2026

Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

386

i10-index

11899

From OpenAlex open data (CC0).

Editorial & policy4
Observed digital preservation (Keepers registry)— snapshot 2026-09-21
CLOCKSSPortico
Norwegian register (HK-dir)— 2027
Level 2 — top tier (~20% of the field's channels)
Open references deposited at Crossref
5%
ORCID iDs in current deposits
4%
Deposits licence metadata at Crossref
✓
Identity & continuity2
Source type
journal
NLM unique ID (PubMed)
9007735
Classification(no data)

No data available to the platform for this group

No platform data for: Classification — absence is not a judgment about the journal.

Subject areas

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Cancer Genomics and Diagnostics
Show all subjects (50)
  • Cancer Treatment and Pharmacology
  • Cancer Treatment and Pharmacology
  • Gastric Cancer Management and Outcomes
  • Gastric Cancer Management and Outcomes
  • Lung Cancer Research Studies
  • Lung Cancer Research Studies
  • HER2/EGFR in Cancer Research
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Breast Cancer Treatment Studies
  • Pancreatic and Hepatic Oncology Research
  • Pancreatic and Hepatic Oncology Research
  • Advanced Breast Cancer Therapies
  • Advanced Breast Cancer Therapies
  • Lymphoma Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • Genetic factors in colorectal cancer
  • Genetic factors in colorectal cancer
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Head and Neck Cancer Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Head and Neck Cancer Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Treatment and Research
  • Radiomics and Machine Learning in Medical Imaging
  • Radiomics and Machine Learning in Medical Imaging
  • Esophageal Cancer Research and Treatment
  • Esophageal Cancer Research and Treatment
  • Economic and Financial Impacts of Cancer
  • Economic and Financial Impacts of Cancer
  • Diverse Scientific and Economic Studies
  • Diverse Scientific and Economic Studies
  • Cancer Diagnosis and Treatment
  • Cancer Diagnosis and Treatment
  • Colorectal and Anal Carcinomas
  • Colorectal and Anal Carcinomas
  • Multiple and Secondary Primary Cancers
  • Multiple and Secondary Primary Cancers

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: